Description
Patients with chronic cardiomyopathy may have persistent viral infections in their hearts, particularly with SARS-CoV-2, which targets the ACE2 receptor highly expressed in human hearts. This raises concerns about a potential global heart failure pandemic stemming from COVID-19, an SARS-CoV-2 pandemic in near future. Although faced with this healthcare caveat, there is limited research on persistent viral heart infections, and no models have been established. In this study, we created an SARS-CoV-2 persistent infection model using human iPS cell-derived cardiac microtissues (CMTs). Mild infections sustained viral presence without signif- icant dysfunction for a month, indicating persistent infection. However, when exposed to hypoxic conditions mimicking ischemic heart diseases, cardiac function deteriorated alongside intracellular SARS-CoV-2 reacti- vation in cardiomyocytes and disrupted vascular network formation. This study demonstrates that SARS- CoV-2 persistently infects the heart opportunistically causing cardiac dysfunction triggered by detrimental stimuli such as ischemia, potentially predicting a post COVID-19 era heart failure pandemic.
Contacts
Keizo
Tomonaga
(Contact)
, LabLaboratory of RNA Viruses, Department of Virus Research, Institute for Life and Medical Sciencesoratory for Developmental Dynamics
, Kyoto University
Hidetoshi
Masumoto
(Contact)
, Clinical Translational Research Program, Center for Biosystems Dynamics Research
, RIKEN
Kozue
Murata
(Imaging Contributor)
, Clinical Translational Research Program, Center for Biosystems Dynamics Research
, RIKEN
UBERON
GO: Biological processes
cardiac muscle contraction (GO:0060048), viral process (GO:0016032) (
GO:0016032)
viral process (GO:0016032) (
GO:0016032)
cardiac muscle contraction (GO:0060048) (
GO:0060048)
Reagent or Compound
Concentration
Fold Dilution
SARS-CoV-2/UT-NCGM02/Human/2020/Tokyo
SARS-CoV-2/UT-NCGM02/Human/2020/Tokyo
SARS-CoV-2/UT-NCGM02/Human/2020/Tokyo
SARS-CoV-2/UT-NCGM02/Human/2020/Tokyo
SARS-CoV-2/UT-NCGM02/Human/2020/Tokyo
SARS-CoV-2/UT-NCGM02/Human/2020/Tokyo
X scales
NA,
566 micrometer/pixel,
Y scales
NA,
566 micrometer/pixel,
T scales
0.04 seconds,
0.07 seconds,
NA,
Channels
1 channel,
3 channel,
Contrast enhancing methods
Resolution enhancing methods
Sample preparation methods
Body
Olympus-Evident CKX53
Objective
Olympus-Evident PLCN4X
Objective
KEYENCE PlanFluorite LD 40x 0.60-3.30-2.20mm Ph2:Default
Dataset name
Organism
Gene / Protein
Dimensions
File size
SSBD:OMERO
Download
Homo sapiens (NCBI:txid9606)
NA
10.9MB
Homo sapiens (NCBI:txid9606)
640x480
8.3MB
Homo sapiens (NCBI:txid9606)
640x480
7.3MB
Homo sapiens (NCBI:txid9606)
NA
123MB
Homo sapiens (NCBI:txid9606)
NA
213MB
Homo sapiens (NCBI:txid9606)
NA
158MB
Homo sapiens (NCBI:txid9606)
NA
179MB
Homo sapiens (NCBI:txid9606)
640x480
1.2MB
Homo sapiens (NCBI:txid9606)
640x480
1.3MB
Homo sapiens (NCBI:txid9606)
640x480
1.4MB